Article Text

Download PDFPDF

P117 Enhancing neurothrombectomy procedures with iVascular devices (iNedit, iNdeep, and iNtercept): first results from the SEMTIC study
Free
  1. Juan MacHo1,
  2. Oscar Chirife2,
  3. Antonio Lopez1,
  4. Pedro Vega3,
  5. Fernando Delgado4,
  6. Alejandro Tomasello5,
  7. Manuel Moreu6,
  8. Carlos Castaño7,
  9. Carlos Domínguez8,
  10. Fernando Aparici9,
  11. Laura Domingo-Rodriguez10,
  12. Carla Agustí10,
  13. Sara Pich10
  1. 1Hospital Clinic of Barcelona, Barcelona, Spain
  2. 2Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
  3. 3Department of Radiology, Hospital Universitario Central de Asturias, Oviedo, Spain
  4. 4H. Reina Sofia de Cordoba
  5. 5Interventional Neuroradiology Section, Vall d Hebron University Hospital, Barcelona, Spain
  6. 6Hospital San Carlos Madrid
  7. 7H. Germans Trias i Pujol
  8. 8Interventional Neuroradiology, Hospital General Universitario Alicante, Alicante, Spain
  9. 9Department of Radiology, HU La Fe, Valencia, Spain
  10. 10iVascular Clinical Department, Sant Vicenç dels Horts, Barcelona

Abstract

Introduction The iVascular neurothrombectomy devices, which include a balloon distal access catheter (iNedit), a microcatheter (iNdeep), and a stent retriever (iNtercept), have been strategically designed to incorporate the benefits of temporary proximal blood flow restriction via a balloon situated 5 cm from the catheter tip. This setup, paired with a guiding distal access catheter, facilitates clot removal through the combined action of a stent retriever and distal aspiration.

Aim of Study To assess the efficacy and safety of three devices (iNedit, iNdeep, and iNtercept) in mechanical thrombectomy for patients with acute ischemic stroke due to large vessel occlusion, presented within 24 hours from symptoms onset.

Methods SEMTIC is a prospective, single-arm, multi-center study with blinded outcomes assessment. Efficacy endpoints: successful reperfusion (eTICI≥2b) within three passes and mRS 0-2 at 90 days. Safety endpoints: all-cause mortality at 90 days, symptomatic intracranial hemorrhage, and embolization in a new territory.

Results A total of 115 patients participated (mean age: 73.7 ± 10.5 years; 53.9% female). Successful reperfusion was 80% (95% CI: 72% to 86%) surpassing non-inferiority proportion reported in literature. Good functional outcomes (mRS 0-2): 56% (46%, 65%). All-cause 90-day mortality: 13.9% (95% CI: 8.2% to 21.6%). Symptomatic intracranial hemorrhage: 1.7% (95% CI: 0.5% to 6.1%). Embolization in a new territory: 5.2% (95% CI: 2.1% to 11.1%).

Conclusion The combination of three iVascular devices proved to be highly effective in mechanical thrombectomy, demonstrating non-inferiority in successful reperfusion parameters with no safety concerns.

Disclosure of Interest no.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.